Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP

Peer Review reports

Original Submission
30 Jun 2021	Submitted	Original manuscript
9 Nov 2021	Reviewed	Reviewer Report - Kirsty Loudon
16 Nov 2021	Author responded	Author comments - Christelle Le GAll-Ianotto
Resubmission - Version 2
16 Nov 2021	Submitted	Manuscript version 2
Publishing
23 Nov 2021	Editorially accepted
19 Dec 2021	Article published	10.1186/s13063-021-05864-8

Back to article page